SLC5A2 and diabetes mellitus: These results encourage efforts to better understand non-psychoactive phytocannabinoids to minimize psychoactive effects and provide safety for chronic diseases, such as diabetes, while exploring their direct or indirect SGLT2-modulating capabilities.